Skip to content

Depression: all studies

Page 171 of 1,037: studies 1,701 to 1,710 of 10,363, newest first. Back to the depression overview

Research

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.

JAMA Network Open August 1, 2023 Chunfeng Xiao, Jia Zhou, Anning Li et al.

Importance: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. Objective: To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral...

Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.

Journal of Psychopharmacology August 2023 Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li et al.

Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear. We enrolled 65 patients with TRD, comprising 33 who received a single infusion of 0.5 mg/kg ketamine and 32 who received a placebo infusion. The...

DOI: 10.1177/02698811231182107 (opens in new tab) Full text (opens in new tab) Ketamine Antisuicidal effect Response inhibition Working memory

Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression.

Journal of Psychopharmacology August 2023 Matthew Burrows, Vasileia Kotoula, Ottavia Dipasquale et al.

Resting state connectivity studies link ketamine's antidepressant effects with normalisation of the brain connectivity changes that are observed in depression. These changes, however, usually co-occur with improvement in depressive symptoms, making it difficult to attribute these changes to ketamine's effects per se. Our aim is to examine the effects of ketamine in brain connectivity, 2 h after...

Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.

Journal of Psychiatric Research August 1, 2023 Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia-Melo et al.

There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at...

Empirical evidence for the neurocognitive effect of nitrous oxide as an adjunctive therapy in patients with treatment resistant depression: A randomized controlled study.

Psychiatry Research August 1, 2023 Jin Liu, Xiaotian Zhao, Xiyu Wei et al.

Nitrous oxide (N2O) has demonstrated an antidepressant effect for treatment-resistant depression (TRD), but no studies investigated the effects of N2O on different cognition domains. This study aimed to test whether N2O would display pro-cognitive effects. We conducted a double-blinded, placebo-controlled, randomized controlled trial, 44 patients with TRD were randomized to N2O group (one-hour...

Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.

Journal of Affective Disorders August 1, 2023 Mu-Hong Chen, Ya-Mei Bai, Hui-Ju Wu et al. 7 citations

OBJECTIVE Previous studies have found an association between klotho, an anti-aging hormone, and major depressive disorder. However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown. METHODS In total, 48 patients with TRD and strong suicidal ideation were randomly assigned to a single 0.5 mg/kg ketamine or 0.045...

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

Pharmaceuticals August 1, 2023 Boney Joseph, Nicolas A. Nunez, Simon Kung et al. 14 citations

Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial ketamine/esketamine treatment among patients with TRD with or without lamotrigine therapy. In this...

Ketamine for the treatment of major depression: a systematic review and meta-analysis

EClinicalMedicine August 1, 2023 Stevan Nikolin, Anthony Rodgers, Andreas Schwaab et al. 166 citations

Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression. However, uncertainties remain regarding comparative efficacy, dosage, and the time course of response. Methods: In this systematic review and meta-analysis, we searched Embase, Medline,...

Using Meditation to Reduce Stress, Anxiety, and Depression in Nursing Students.

Journal of Nursing Education August 1, 2023 Shohini Holden, Kathleen A O'Connell 19 citations

Nursing students experience higher rates of mental health issues than other college students. This study examined the effect of a mindfulness meditation intervention on nursing students' levels of self-reported depression, stress, and anxiety. This randomized, experimental study implemented an online mindfulness meditation intervention for an experimental group of nursing students and provided...

Effects of a prenatal mindfulness program on longitudinal changes in stress, anxiety, depression, and mother–infant bonding of women with a tendency to perinatal mood and anxiety disorder: a randomized controlled trial

BMC Pregnancy and Childbirth July 31, 2023 Wan-Lin Pan, Li-Chiu Lin, L. Kuo et al.

Background Stress is a risk factor for poor physical and mental health, affecting new mothers’ ability, especially those with perinatal mood and anxiety disorders, to maintain their everyday lives. Over the past 50 years, global incidences of depression and anxiety disorders have increased, reaching pandemic levels. These incidences represent major public health issues that are challenging to...